Individual bioequivalence - Has its time come?

European Journal of Pharmaceutical Sciences

Volumn 6, Issue 4, 1998, Pages 271-277

  Endrenyi, Laszlo ^a   Midha, Kamal K ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Average bioequivalence; Individual bioequivalence; Population bioequivalence; Regulatory process

Indexed keywords

ARTICLE; BIOEQUIVALENCE; DRUG FORMULATION; FOOD AND DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL;

HUMANS; PHARMACEUTICAL PREPARATIONS; THERAPEUTIC EQUIVALENCY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0032189788     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(97)10021-5     Document Type: Article

References (33)

1. Anderson, S., 1993. Individual bioequivalence: A problem of switchability (with discussion). Biopharm. Rep. 2 (2), 1-11.
2. Anderson, S., 1995. Current issues of individual bioequivalence. Drug Inform. J. 29, 961-964.
3. Anderson, S., Hauck, W.W., 1990. Considerations of individual bioequivalence. J. Pharmacokin. Biopharm. 18, 259-273.
4. Blume, H.H., Midha, K.K., 1993. Conference report-Bio-International 92, Conference on Bioavailability, Bioequivalence and Pharmacokinetic Studies. In: Midha, K.K., Blume, H.H. (Eds.), Bio-International: Bioavailability, Bioequivalence and Pharmacokinetics. Medpharm, Stuttgart, pp. 13-23.
5. Boddy, A.W., Snikeris, F.C., Kringle, R.O., Wei, G.C.G., Opperman, J.A., Midha, K.K., 1995. An approach for widening the bioequivalence limits in the case of highly variable drugs. Pharm. Res. 12, 1865-1868.
6. Cartwright, A.C., Gundert-Remy, U., Rauws, G., McGilveray, I., Salmonson, T., Walters, S., 1991. International harmonization and consensus DIA meeting on bioavailability and bioequivalence testing requirements and standards. Drug Inform. J. 25, 471-482.
7. Chen, M.L., 1997. Individual bioequivalence - A regulatory update. J. Biopharm. Stat. 7, 5-11.
8. Efron, B., Tibshirani, R.J., 1993. An Introduction to the Bootstrap. Chapman and Hall, New York.
9. Ekbohm, G., Melander, H., 1989. The subject-by-formulation interaction as a criterion of interchangeability of drugs. Biometrics 42, 1249-1254.
10. Endrenyi, L., 1994. A method for the evaluation of individual bioequivalence. Int. J. Clin. Pharmacol. Ther. Toxicol. 32, 497-508.
11. Endrenyi, L., 1997. Some issues for the consideration of individual bioequivalence. J. Biopharm. Stat. 7, 35-39.
12. Endrenyi, L., Schulz, M., 1993. Individual variation and the acceptance of average bioequivalence. Drug Inform. J. 27, 195-201.
13. FDA (1997). Draft Guidance on Individual and Population Bioequivalence. Food and Drug Administration, in press.
14. Gaffney, M., 1992. Variance components in comparative bioavailability studies. J. Pharm. Sci. 81, 315-317.
15. Goosen, R.M., 1996. A Simulation Study to Determine Sample Sizes for the Assessment of Individual Bioequivalence. M.M.Sc. thesis, University of Orange Free State, Bloemfontein, South Africa, 117 pp.
16. Gould, A.L., 1997. Discussion of individual bioequivalence by M.-L. Chen. J. Biopharm. Stat. 7, 23-29.
17. Hauck, W.W., Anderson, S., 1992. Types of bioequivalence and related considerations. Int. J. Clin. Pharmacol. Ther. 30, 181-187.
18. Hauck, W.W., Anderson, S., 1994. Measuring switchability and prescribability: When is average bioequivalence sufficient?. J. Pharmacokin. Biopharm. 22, 551-564.
19. Hauck, W.W., Bois, F.Y., Hyslop, T.Y., Gee, L., Anderson, S., 1997. A parametric approach to population bioequivalence. Stat. Med. 16, 441-454.
20. Hauck, W.W., Chen, M.-L., Hyslop, T., Patnaik, R., Schuirmann, D., Williams, R., 1996. Mean difference vs. variability reduction: tradeoffs in aggregate measures for individual bioequivalence. Int. J. Clin. Pharmacol. Ther. 34, 535-541.
21. Holder, D.J., Hsuan, F., 1993. Moment-based criteria for determining bioequivalence. Biometrika 80, 835-846.
22. Jones, B., Kenward, M.G., 1989. Design and Analysis of Cross-over Trials. Chapman and Hall, London.
23. Kimanani, E.K., Potvin, D., Lalonde, R.L., 1996. An exact confidence interval for a moment-based scaled criterion for individual bioequivalence (Abstract). Pharm. Res. 13, S478.
24. Liu, J., Chow, S.-C., 1997. Some thoughts on individual bioequivalence. J. Biopharm. Stat. 7, 41-48.
25. Midha, K.K., Rawson, M.J., Hubbard, J.W., 1997. Individual and average bioequivalence of highly variable drugs and drug products. J. Pharm. Sci. 86, 1193-1197.
26. Ormsby, E., 1994. Statistical methods in bioequivalence. In: Jackson, A.J. (Ed.), Generics and Bioequivalence. CRC Press, Boca Raton, pp. 1-27.
27. Schall, R., Luus, H.E., 1993. On population and individual bioequivalence. Stat. Med. 12, 1109-1124.
28. Schall, R., 1995. A unified view of individual, population, and average bioequivalence. In: Blume, H.H., Midha, K.K. (Eds.), Bio-International 2: Bioavailability, Bioequivalence and Pharmacokinetic Studies. Medpharm, Stuttgart, pp. 91-106.
29. Schall, R., Williams, R.L., 1996. Towards a practical strategy for assessing individual bioequivalence. J. Pharmacokin. Biopharm. 24, 133-149.
30. Schuirmann, D.J., 1987. A comparison of the two one-sided test procedure and the power approach for assessing the bioequivalence of average bioavailability. J. Pharmacokin. Biopharm. 15, 657-680.
31. Shah, V.P, Yacobi, A., Barr, W.H., Benet, L.Z., et al., 1996. Evaluation of orally administered highly variable drugs and drug formulations. Pharm. Res. 13, 1590-1594.
32. Sheiner, L.B., 1992. Bioequivalence revisited . Stat. Med. 11, 1777-1788.
33. Steinijans, V.W., Hauschke, D., 1997. Individual bioequivalence - a European perspective. J. Biopharm. Stat. 7, 31-34.